Mode
Text Size
Log in / Sign up
N/A N=198 Randomized Single-blind

Evaluation of the Cosmetic Performance of AIR OPTIX® COLORS

Cosmetic Appearance

Enrolled (actual)
198
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcome: Primary: Overall Preference — 49.1; 24.6 Percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Lotrafilcon B contact lens with color (Device); Phemfilcon A contact lens with color (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
CIBA VISION
Primary completion
Dec 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Preference
49.1; 24.6
PRIMARY
Initial Comfort Preference
55.1; 23.4
PRIMARY
Appearance Preference
36.5; 23.4
PRIMARY
Subjective Rating of Initial Comfort
8.6; 7.5
PRIMARY
Percent Positive Responses: Cosmetic Appearance (Strongly Agree, Agree)
84.9; 77.0; 78.9; 81.3; 81.3; 75.8
PRIMARY
Percent Positive Purchase Intent (Definitely Would Buy, Probably Would Buy)
80.2; 59.9

Summary

The purpose of this study was to evaluate the cosmetic performance of AIR OPTIX® COLORS contact lenses compared to FRESHLOOK® COLORBLENDS contact lenses in habitual FRESHLOOK® COLORBLENDS contact lens wearers.

Eligibility Criteria

Inclusion Criteria

  • Sign written Informed Consent document. If under legal age of consent, legally authorized representative must sign Informed Consent document and subject must sign Assent document.
  • Have spectacles that provide acceptable near vision to wear over study lenses as needed to evaluate cosmetics of the lenses.
  • Habitually wear FRESHLOOK® COLORBLENDS lenses at least two days per week.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Eye injury or surgery within twelve weeks of enrollment in this trial.
  • Pre-existing ocular irritation that would preclude contact lens fitting.
  • Currently enrolled in any clinical trial.
  • Evidence of systematic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses or use of accessory solutions as determined by the investigator.
  • Any use of medications for which contact lens wear could be contraindicated as determined by the investigator.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01398787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search